- Technology

Biologics development is lengthy and costly. It takes more than 2 years to bring a candidate therapy to human trials. This prevents timely intervention during infectious disease outbreaks resulting in millions of fatalities every year.

Conventional Biomanufacturing

TYCHAN’s Integrated Rapid Response Platform

Tychan’s technology platform integrates innovations in data analytics, bio-manufacturing processes and regulatory sciences to bring candidate biologics to human trials faster. We use convergent analytics to define molecular fingerprints for reliable tracking of safety and potency of biologics throughout the manufacturing process - from cell selection to final product. Using this approach, we have brought two first-in-class therapeutics - Tyzivumab and TY014, from candidate to IND filing in less than 10 months.

- Pipeline


Tyzivumab is a first-in-class monoclonal antibody designed and engineered to neutralize Zika virus by binding to a specific quaternary epitope of the envelope (E) protein on virus surface.

About Zika Virus

Zika virus (ZIKV) has emerged to become a major health concern in many parts of the tropical world. This flavivirus is transmitted by the same Aedes mosquitoes that spread the dengue virus (DENV), and hence ZIKV has the potential to be as widely distributed as DENV globally. Whilst mostly a mild, self-limiting viral infection, epidemiological observations now reveal a strong link between infection of pregnant women and severe neurological complications, including microcephaly, in the developing fetus. Rarely, infection in otherwise healthy adults can also lead to the development of neurological complications in the form of Guillain-Barré syndrome. With no approved vaccine, there is an urgent need for a safe therapy to reduce viral spread and lower the risk of congenital infection and Guillain-Barré syndrome.


TY014 is a first-in-class monoclonal antibody designed and engineered to neutralize multiple strains of Yellow Fever virus by binding to a specific epitope of the envelope (E) protein found on the surface of the virus.

About Yellow Fever Virus

Yellow Fever (YF) is a mosquito-borne acute viral haemorrhagic disease caused by the Yellow Fever virus (YFV). Nearly 15% of the patients infected with YFV develop life threatening illness involving haemorrhage, jaundice, and shock. Of these 20-50% die of the disease. YFV is currently endemic to 47 countries in Africa, Central and South America and has been responsible for several hundred cases and deaths in Brazil alone. Currently there is no treatment available for YF. Although an approved vaccine does exist and is highly effective, protecting > 90% of the vaccines, surge in global demand due to outbreaks, as well as inadequate supply has created a global shortage of the vaccine leaving millions at risk should a major outbreak occur.

- News